Milbemycin/Lufenuron/Pzq Chew

Verify with FDA CVM →

4,022 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
4,022
Total Reports
64
Deaths Reported
160.0%
Death Rate

Active Ingredients

Milbemycin/Lufenuron/Pzq Chew

Administration Routes

OralUnknownDentalOculonasal

Species Affected

Dog 3,934
Unknown 88

Most Affected Breeds

Crossbred Canine/dog 1,084
Retriever - Labrador 430
Shepherd Dog - German 191
Retriever - Golden 186
Dog (unknown) 128
Pit Bull 110
Shepherd Dog - Australian 97
Beagle 93
Unknown 89
Chihuahua 78

Most Reported Reactions

Lack of efficacy (endoparasite) - heartworm 1,316
Lack of efficacy (endoparasite) - hookworm 630
Vomiting 448
Lack of efficacy (endoparasite) - roundworm NOS 340
Lack of efficacy (ectoparasite) - flea 214
Emesis (multiple) 208
Lack of efficacy (endoparasite) - tapeworm 162
Diarrhoea 155
Drug dose omission 131
Lack of efficacy (endoparasite) - whipworm 121
Lethargy (see also Central nervous system depression in Neurological) 101
Seizure NOS 90

Outcome Breakdown

Ongoing
2,854 (72.5%)
Recovered/Normal
867 (22.0%)
Outcome Unknown
121 (3.1%)
Died
32 (0.8%)
Euthanized
32 (0.8%)
Recovered with Sequela
29 (0.7%)

Data Summary

Metric Value
Total adverse event reports 4,022
Reports involving death 64
Case-fatality rate (reported events) 160.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Milbemycin/Lufenuron/Pzq Chew Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 4,022 adverse event reports referencing Milbemycin/Lufenuron/Pzq Chew, including 64 reports in which the animal died — a 160.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Milbemycin/Lufenuron/Pzq Chew. Reported administration routes include Oral, Unknown, Dental, Oculonasal. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Milbemycin/Lufenuron/Pzq Chew reports are Dog (3,934 reports), Unknown (88 reports), with Dog accounting for the largest share. Within those species, Crossbred Canine/dog (1,084), Retriever - Labrador (430), Shepherd Dog - German (191) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Milbemycin/Lufenuron/Pzq Chew are Lack of efficacy (endoparasite) - heartworm (1,316), Lack of efficacy (endoparasite) - hookworm (630), Vomiting (448), Lack of efficacy (endoparasite) - roundworm NOS (340). Of the 3,935 reports with a coded outcome, Ongoing is the leading category at 72.5%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Milbemycin/Lufenuron/Pzq Chew.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial